CubaTuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.047 (0.046–0.048) 0.41 (0.41–0.42)
Mortality (HIV+TB only) 0.01 (<0.01–0.045) 0.09 (0–0.39)
Incidence  (includes HIV+TB) 0.8 (0.69–0.92) 7 (6–8.1)
Incidence (HIV+TB only) 0.074 (0.063–0.085) 0.65 (0.55–0.75)
Incidence (MDR/RR-TB)** 0.025 (0.011–0.04) 0.22 (0.1–0.35)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.017 (<0.01–0.031) 0.17 (0.069–0.26) 0.18 (0.073–0.29)
Males 0.038 (0.025–0.051) 0.58 (0.46–0.71) 0.62 (0.48–0.76)
Total 0.055 (0.04–0.07) 0.75 (0.68–0.81) 0.8 (0.69–0.92)
TB case notifications, 2015  
Total cases notified 753
Total new and relapse 698
          - % tested with rapid diagnostics at time of diagnosis 7%
          - % with known HIV status 100%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.07 (0.04–0.11)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 67 10%
          - on antiretroviral therapy 63 94%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  17
(5–29)
Estimated % of TB cases with MDR/RR-TB 2.2% (0.82–4.8) 4.2% (0.51–14)  
% notified tested for rifampicin resistance 41% 42% 307
MDR/RR-TB cases tested for resistance to second-line drugs   4
Laboratory-confirmed cases MDR/RR-TB: 9, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 9, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 82% 729
Previously treated cases, excluding relapse, registered in 2014 23% 13
HIV-positive TB cases, all types, registered in 2014 67% 87
MDR/RR-TB cases started on second-line treatment in 2013 100% 3
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 85%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 26
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data